Contraindicated in:
Use Cautiously in:
CV: hypotension, bradycardia.
Derm: flushing, sweating.
EENT: blurred vision, diplopia, miosis.
Endo: adrenal insufficiency.
GI: constipation, dry mouth, nausea, vomiting.
GU: urinary retention.
Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams.
Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA).
Misc: physical dependence, psychological dependence, tolerance.
Drug-Drug:
Drug-Natural Products:
(Generic available)
Hepatic Impairment
Renal Impairment
Dilaudid, Dilaudid-HP, Exalgo
Absorption: Well absorbed following oral, rectal, SUBQ, and IM administration. Extended-release product results in an initial release of drug, followed by a 2nd sustained phase of absorption.
Distribution: Widely distributed. Crosses the placenta; enters breast milk.
Metabolism/Excretion: Mostly metabolized by the liver.
Half-life: Oral (immediate-release), or injection: 24 hr; Oral (extended-release): 815 hr.
(analgesic effect)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO-IR | 30 min | 3090 min | 45 hr |
PO-ER | unknown | unknown | unknown |
SUBQ | 15 min | 3090 min | 45 hr |
IM | 15 min | 3060 min | 45 hr |
IV | 1015 min | 1530 min | 23 hr |
Rect | 1530 min | 3090 min | 45 hr |
NDC Code*